Young Suk Park

10.7k total citations · 2 hit papers
227 papers, 6.3k citations indexed

About

Young Suk Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Young Suk Park has authored 227 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Oncology, 95 papers in Pulmonary and Respiratory Medicine and 69 papers in Surgery. Recurrent topics in Young Suk Park's work include Colorectal Cancer Treatments and Studies (80 papers), Gastric Cancer Management and Outcomes (54 papers) and Pancreatic and Hepatic Oncology Research (40 papers). Young Suk Park is often cited by papers focused on Colorectal Cancer Treatments and Studies (80 papers), Gastric Cancer Management and Outcomes (54 papers) and Pancreatic and Hepatic Oncology Research (40 papers). Young Suk Park collaborates with scholars based in South Korea, United States and Japan. Young Suk Park's co-authors include Joon Oh Park, Won Ki Kang, Jeeyun Lee, Ho Yeong Lim, Se Hoon Park, Seung Tae Kim, Kyoung‐Mee Kim, Su Jin Lee, Yong‐Seok Jee and Keunchil Park and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Young Suk Park

222 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

2012 474 citations Jung Hun Kang, Sung Yong Oh et al. profile →
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

2015 297 citations Se Hoon Park, Tae Sung Sohn et al. profile →

Peers

Countries citing papers authored by Young Suk Park

Since Specialization

Citations

This map shows the geographic impact of Young Suk Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young Suk Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young Suk Park more than expected).

Fields of papers citing papers by Young Suk Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young Suk Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young Suk Park. The network helps show where Young Suk Park may publish in the future.

Co-authorship network of co-authors of Young Suk Park

This figure shows the co-authorship network connecting the top 25 collaborators of Young Suk Park. A scholar is included among the top collaborators of Young Suk Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young Suk Park. Young Suk Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 2025 ·The Lancet ·J. Randolph Hecht, Young Suk Park, Josep Tabernero, Myung Ah Lee, Soo Hyun Lee, A.C. Virgili Manrique, Marc Van den Eynde, Elisa Fontana, Marwan Fakih, Gholamreza Asghari, (unknown), Alexander Stein, Olivier Dubreuil, Lubomir Bodnar, Cixin He, Guan Wang, (unknown), Cathy Eng, Anwaar Saeed	3
2	Prospective, open‐label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study 2023 ·Asia-Pacific Journal of Clinical Oncology ·Tsai‐Sheng Yang, Hong‐Hwa Chen, (unknown), Tae Won Kim, Jong Gwang Kim, Joong Bae Ahn, (unknown), Johnson Lin, Gwo Fuang Ho, (unknown), Sally Temraz, Matthew Burge, Clarinda Chua, (unknown), Young Suk Park	0
3	Genomic and Transcriptomic Characterization of Gastric Cancer with Bone Metastasis 2023 ·Cancer Research and Treatment ·Soo Jin Oh, Soo Kyung Nam, Keun‐Wook Lee, Hye Seung Lee, Yujun Park, Yoonjin Kwak, Kyu Sang Lee, Ji‐Won Kim, Jin Won Kim, Min-Su Kang, Young Suk Park, (unknown), Yun‐Suhk Suh, Do Joong Park, Hyung‐Ho Kim	8
4	Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study 2022 ·European Journal of Cancer ·Joo‐Hyun Park, Kyungdo Han, Jung Yong Hong, Young Suk Park, (unknown), (unknown)	15
5	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer 2021 ·Clinical Cancer Research ·Seung Tae Kim, Simon A. Smith, Peter G. Mortimer, Arsène‐Bienvenu Loembé, (unknown), Kyoung‐Mee Kim, Claire Smith, Sophie E. Willis, Itziar Irurzun‐Arana, Aliénor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, Jeeyun Lee	61
6	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system 2019 ·PLoS ONE ·Jang Ho Cho, Ju Sun Kim, Seung Tae Kim, Jung Yong Hong, Joon Oh Park, Young Suk Park, Do-Hyun Nam, Dong Woo Lee, Jeeyun Lee	3
7	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis 2018 ·Molecular Cancer Therapeutics ·Hee Kyung Kim, (unknown), Heejin Bang, Hee Cheol Kim, Woo Yong Lee, Seong Hyeon Yun, Jeeyun Lee, Su Jin Lee, Young Suk Park, Kyoung‐Mee Kim, Won Ki Kang	40
8	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial 2018 ·Journal of the Korean Gastric Cancer Association ·(unknown), Kyoung‐Mee Kim, Min Gew Choi, Jun Ho Lee, Tae Sung Sohn, Jae-Moon Bae, (unknown), Su Jin Lee, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park	9
9	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer 2018 ·Clinical Colorectal Cancer ·Jeeyun Lee, Seung Tae Kim, Sungju Park, Su Jin Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, (unknown), (unknown), Kyoung‐Mee Kim, Myung‐Ju Ahn, Won Ki Kang, Young Suk Park	20
10	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial 2018 ·Journal of Cancer ·Sung Won Lim, Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Seung Tae Kim	5
11	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo 2017 ·Cancer Chemotherapy and Pharmacology ·Makoto Ueno, (unknown), Masafumi Ikeda, Hiroshi Ishii, Nobumasa Mizuno, Taketo Yamaguchi, Tatsuya Ioka, Do Youn Oh, Wataru Ichikawa, Takuji Okusaka, Yutaka Matsuyama, (unknown), (unknown), Young Suk Park, Junji Furuse	8
12	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer 2017 ·Journal of Cancer ·Seung Tae Kim, Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park	19
13	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer 2017 ·Targeted Oncology ·Michael Michael, Yung‐Jue Bang, Young Suk Park, Yoon‐Koo Kang, Tae Min Kim, Oday Hamid, Donald Thornton, Sonya C. Tate, Eyas Raddad, Jeanne Tie	68
14	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects 2015 ·Supportive Care in Cancer ·In Gyu Hwang, Jung Hun Kang, Sung Yong Oh, Suee Lee, (unknown), Ki‐Hoon Song, Choonhee Son, Min Jae Park, Myung Hee Kang, (unknown), Jeeyun Lee, Young Suk Park, (unknown), Hyun Jung Kim, Chan Kyu Kim, Seong Yoon Yi, Joung-Soon Jang, Keunchil Park, Hyo-Jin Kim	9
15	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification 2014 ·Molecular Cancer Therapeutics ·Seung Tae Kim, (unknown), Su Jin Lee, Jeeyun Lee, Yoon‐La Choi, Kyoung‐Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, Joon Oh Park	35
16	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial 2014 ·The Lancet Oncology ·Yong Sang Hong, Byung‐Ho Nam, Kyu-pyo Kim, Jeong Eun Kim, Seongjoon Park, Young Suk Park, Joon Oh Park, Sun Young Kim, Tae‐You Kim, Jee Hyun Kim, Joong Bae Ahn, Seok‐Byung Lim, Chang Sik Yu, Jin Cheon Kim, Seong Hyeon Yun, Jong Hoon Kim, Jin‐hong Park, Hee Chul Park, Kyung Hae Jung, Tae Won Kim	265
17	Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer 2013 ·Cancer Chemotherapy and Pharmacology ·Kyung-Hun Lee, Hye Jung Chang, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Sun Young Kim, Keun‐Wook Lee, Jee Hyun Kim, Yong Sang Hong, Tae Won Kim, Young Suk Park, Won Ki Kang, Sang Joon Shin, Joong Bae Ahn, Gyeong Hoon Kang, Seung‐Yong Jeong, Kyu Joo Park, Jae‐Gahb Park, Tae‐You Kim	36
18	Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene 2012 ·PLoS ONE ·Yong‐Seok Jee, Chang Ohk Sung, Eui Jin Lee, (unknown), (unknown), (unknown), Woo Yong Lee, Ho Kyung Chun, (unknown), Young Suk Park	26
19	Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients 2011 ·Cancer ·Hong‐Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong‐Won Kim, Soo‐Youn Lee, Se Hoon Park	73
20	Articles : Detection of the BCR / abl Gene Rearrangement by Reverse Transcriptase Based Polymerase Chain Reaction 1996 ·BMB Reports ·(unknown), Young Suk Park, Yong Woo Kim, (unknown), Yoon Jung Kim	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact